The article 2022 End of Year Review: Cybin was originally published on Microdose. The end of the year is a convenient time to look back and...
Source: Andrew Partheniou 12/20/2022 The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more...
Also a peek at their plans for the year ahead. The post How 5 Psychedelics Companies Fared in 2022 appeared first on Green Market Report.
Cybin (NYSE American: CYBN | NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary...
Scientific community looks for ways to effectively research psilocybin. The post Deeper insight: Natural Psychedelics or Synthetic? appeared first on Green...
Researchers looking more closely at similarities of compounds and responses. The post Psychedelics Research Expands Treatment Focus appeared first on Green...
TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today issued...
Even without revenue, psychedelics companies find financing for ongoing research. The post Psychedelics Companies Report Strong Research Investment appeared...
Even without revenue, psychedelics companies find financing for ongoing research. The post Psychedlics Companies Report Strong Research Investment appeared...
Cybin Inc. (NEO:CYBN | NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the...